Virginia House Bill 1559 (Prior Session Legislation)

---

Spectrum: Moderate Partisan Bill (Democrat 6-1)
Status: Introduced on January 13 2020 - 25% progression, died in committee
Action: 2020-02-04 - Continued to 2021 in Health, Welfare and Institutions by voice vote
Pending: House Health, Welfare and Institutions Committee
Text: Latest bill text (Introduced) [HTML]

Prescription drug price transparency; penalties. Prescription drug price transparency; penalties. Requires pharmaceutical drug manufacturers, pharmacy benefits managers, and health carriers to submit reports containing certain information concerning prescription drug costs to the Commissioner of the Bureau of Insurance (the Commissioner). The measure requires pharmaceutical drug manufacturers' reports to include information on the current wholesale acquisition cost information for FDA-approved drugs sold in or into the Commonwealth by the pharmaceutical drug manufacturer. The bill also requires such manufacturers to submit a report for drugs with a wholesale acquisition cost of at least $50 for a 30-day supply when their wholesale acquisition cost increases by 25 percent or more over the preceding three calendar years or 10 percent or more over the preceding calendar year. The measure requires pharmacy benefits managers to report data on the aggregated rebates, fees, price protection payments, and any other payments collected from pharmaceutical drug manufacturers and the aggregated dollar amount of rebates, fees, price protection payments, and any other payments collected from pharmaceutical drug manufacturers that were health benefit plan issuers or enrollees at the point of sale of a prescription drug. The measure requires health carriers to report the names of the 25 most frequently prescribed drugs across all plans, percent increase in annual net spending for drugs across all plans, percent increase in premiums attributable to drugs across all plans, percentage of specialty drugs with utilization management requirements across all plans, and premium reductions that were attributable to specialty drug utilization management. The measure requires the Commissioner to publish the aggregated data from these reports on a website. The measure authorizes the State Corporation Commission (the Commission) to (i) call public hearings and to subpoena prescription drug manufacturers, pharmacy benefits managers, and health carriers to explain their reports; (ii) conduct audits of data submitted to it; (iii) require these entities to submit a corrective action plan to correct deficiencies in reporting; and (iv) impose penalties of $30,000 per day on any prescription drug manufacturer, pharmacy benefits manager, or health carrier that fails to make a good faith effort to submit a required report within two weeks after receiving written notice from

Prescription drug price transparency; penalties.

Del. Chris Hurst [D]	Del. Dan Helmer [D]	Del. Jeffrey Campbell [R]	Del. Patrick Hope [D]
Del. Clinton Jenkins [D]	Del. Kenneth Plum [D]	Del. Shelly Simonds [D]

Date	Chamber	Action
2020-02-04	House	Continued to 2021 in Health, Welfare and Institutions by voice vote
2020-01-30	House	Referred to Committee on Health, Welfare and Institutions
2020-01-30	House	Referred from Labor and Commerce by voice vote
2020-01-13	House	Referred to Committee on Labor and Commerce
2020-01-13	House	Presented and ordered printed 20104406D

HB1559 (Carry Over) 2020-02-04 - Continued to 2021 in Health, Welfare and Institutions by voice vote

Chapter	Article	Section	Citation Type	Statute Text
38	2	6500	(n/a)	See Bill Text
38	2	6506	(n/a)	See Bill Text

Type	Source
Summary	https://lis.virginia.gov/cgi-bin/legp604.exe?201+sum+HB1559
Text	https://lis.virginia.gov/cgi-bin/legp604.exe?201+ful+HB1559+hil